You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

康寧傑瑞製藥(09966.HK)將公佈藥品研究結果

阿思達克 09-13 08:30
康寧傑瑞製藥(09966.HK)公佈，將於2021年歐洲腫瘤內科學會大會呈列發佈KN046(一種抗PD-L1/CTLA-4雙特異性抗體)及KN026(一種HER2靶向雙特異性抗體)的研究結果，分別爲KN046聯合侖伐替尼用於一線治療晚期不可切除或轉移性肝細胞癌的前瞻性II期臨牀試驗的初步療效及安全性結果、KN026聯合KN046用於治療HER2陽性胃腸腫瘤患者的初步療效及安全性結果，及KN046聯合含鉑雙藥化療作爲治療伴有耐藥性致癌驅動基因突變的晚期NSCLC患者的一線療法。
康宁杰瑞制药-B(09966.HK)
Relevant Stocks
康宁杰瑞制药-B(09966.HK)
Relevant Recommendation
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.